BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis" (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.
Location: France, Occitania, Clapiers
Employees: 1-10
Total raised: $5.4M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | V-Bio Vent... | v-bio.vent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.08.2020 | Series A | $5.4M | - |
Mentions in press and media 1
| Date | Title | Description |
| 27.05.2024 | French biotech startup Biodol Therapeutics secures €7M to treat chronic pain: Know more | Read this article in: Montarnaud-based Biodol Therapeutics, a French biotech company developing next-generation pain treatments, announced on Tuesday, May 21, that it has been awarded €7M by BPI France through the i-DEMO call for projects. ... |